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ABSTRACT 
Infections caused by Enterococcus faecalis (Ef) represent nowadays a relevant health problem. 
We selected Thymidylate synthase (TS) from this organism as a potential specific target for 
antibacterial therapy. We have previously demonstrated that species-specific inhibition of the 
protein can be achieved despite the relatively high structural similarity among bacterial TSs and 
human TS. We had previously obtained the EfTS crystal structure of the protein in complex with 
the metabolite 5-formyl-tetrahydrofolate (5-FTHF) suggesting the protein role as metabolite 
reservoir; however, protein–inhibitors complexes were still missing. In the present work we 
identified some inhibitors bearing the phthalimidic core from our in-house library and we 
performed crystallographic screening towards EfTS. We obtained two X-ray crystallographic 
structures: the first with a weak phthalimidic inhibitor bound in one subunit and 5-
hydroxymethylene-6-hydrofolic acid (5-HMHF) in the other subunit; a second X-ray structure 
complex with methotrexate. The structural information achieved confirm the role of EfTS as an 
enzyme involved in the folate pool system and provide a structural basis for structure-based drug 
design. 
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1. Introduction 
Enterococci can be found in soil, food and water and make up a significant portion of the normal 
gut flora of humans and animals. As for other bacteria of the gut flora, enterococci can also 
cause infectious diseases. Typical enterococcal infections occur in immunosuppressed patients 
and in hospitalisedhospitalized patients suffering from a wide spectrum of severe illnesses. 
Enterococci nowadays rank second to third in frequency among bacteria isolated from 
hospitalisedhospitalized patients. They can be often isolated from urinary tract infections, intra-
abdominal and pelvic infections, bacteremias, wounds, tissue infections and endocarditis as part 
of a polymicrobial flora. Enterococcus faecalis (Ef) and Enterococcus faecium are the most 
prevalent species cultured from humans and they are present in more than 90% of clinical 
isolates. Enterococcus faecalis accounts for 80-90% of clinical strains, while Enterococcus 
faecium for only 5-10%. Some strains of E. faecalis and many of E. faecium are resistant to 
multiple antimicrobials [1]. The identification of new antibiotics targeting Enterococci infections 
is challenging since no specific antibacterial agents are known so far. This encourages the 
starting of active drug discovery programs. Molecules targeting the Enterococci folate pathway 
represent a source of potential and specific drugs able to inhibit the bacterial folate pathway 
without altering, in principle, the mammalian cells. In our antibacterial discovery programs we 
have identified some lead compounds bearing a phthalimide moiety targeting bacterial 
Lactobacillus casei (Lc) and Escherichia coli (Ec) thymidylate synthase (TS) and able to 
discriminate between the bacterial and the host (human) protein. This selectivity led to the 
discovery of antibacterial agents with a low toxicity [2–10]. TS (EC: 2.1.1.45) catalysescatalyzes 
the reductive methylation of 2′-deoxyuridine-5′-monophosphate (dUMP) to 2′-deoxythymidine-
5′-monophosphate (dTMP), assisted by the cofactor N5,N10-methylene tetrahydrofolate (MTHF) 
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[11,12]. TS is the only synthetic source of dTMP in human cells, thus it represents a major target 
for the design of chemotherapeutic agents [13]. The well knownwell-known anticancer agents, 5-
fluorouracil (the prodrug of 5-fluoro-2’-deoxyuridine monophosphate), methotrexate (MTX) and 
raltitrexed (Figure 1), are classical TS inhibitors belonging to the antimetabolite class. In our 
previous work, compound α156 (Figure 1) had been proposed as an antibacterial lead able to 
face vancomycin-resistant infections caused by gram positive bacteria such as Staphylococcus 
aureus. This molecule also inhibited the Enterococcus faecalis clinical isolates and showed a low 
toxicity towards human cells [7]. In a parallel work we had identified a library of phthalimidic 
derivatives, 4-methylisoindoline-1,3-dione N-derivatives (I, Figure 1) and 4-(aminomethyl)-2-
methylisoindoline-1,3-dione derivatives substituted at the amino position (II, Figure 1), that 
presented inhibitory activity against bacterial TS enzymes. These phthalimidic derivatives 
inhibited also Enterococcus faecalis TS (EfTS), with the best inhibitors showing Ki in the range 
of 2-8 µM. These compounds exhibited a competitive behaviourbehavior with respect to the 
folate cofactor and a significant selectivity towards bacterial TS [8]. EfTS X-ray crystal structure 
of the native protein had been obtained [14]. According to structural analysis, the protein 
crystallized in a ternary complex where a folate substrate analogue, 5-formyl-tetrahydrofolate (5-
FTHF), originating from the bacterial metabolites pool, co-crystallized with the enzyme. Thus, 
we can conclude that EfTS could be considered a reservoir for folate substrates in the bacteria 
folate dependent metabolism. Although no structural information about EfTS-inhibitors 
complexes are available yet, we could suppose that the target druggability is influenced by the 
presence of the folate metabolites inside the bacterial cell and that higher affinity inhibitors are 
necessary to displace 5-FTHF. Aiming to obtain X-ray crystallographic structures to gain 
additional information on EfTS target druggability and to carry out further structure-based drug 
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design studies, we analysedanalyzed our in-house library based on a N-substituted phthalimide 
scaffold bearing a flexible chain linked to the nitrogen in position 2. In details, 56 compounds 
(Chart 1 and 2) were tested against EfTS, EcTS and human TS (hTS). In the present work, X-ray 
crystallographic screenings were carried out and one X-ray crystallography complex with a 
protein inhibitor, (S)-12, was obtained. In addition, we solved a the X-ray crystal structure of 
EfTS in complex with methotrexate (MTX), a known folate analogue. These studies represent an 
important starting point for a structure-based drug design aimed at identifying new antibacterial 
agents against Enterococcus faecalis infections. 
 
2. Results and discussion 
2.1. Library Selection and Compound Synthesis 
With the aim of exploring the chemical space of the phthalimide core, a library of 56 compounds 
(Charts 1 and 2) was selected from our in-house libraries (for details see experimental section), 
previously synthesized as intermediates for the preparation of compounds with different 
pharmacological activities [15–33]. These compounds underwent in vitro screening towards 
EfTS, hTS and EcTS. All the molecules of the new library show an N-substituted phthalimide 
ring (III, Figure 1). The majority of the compounds have an aromatic ring in the side-chain 
linked to position 2 of the phthalimide moiety. In our previously published library the aromatic 
moiety in the side-chain was directly linked to the nitrogen in position 2 (I, Figure 1), whereas in 
the present work almost all the compounds have a spacer between the phthalimide core and the 
aromatic system of the side-chain, thus being more flexible. Few compounds (27–31, 34, 56) 
have a non aromaticnon-aromatic side-chain with a lower steric hindrance. This novel 
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phthalimide library includes several chiral compounds (1–8, 12, 13, 17, 21, 27–34, 40–43, 50, 
51, 56) and for some of them we explored the biological profile of both the racemic mixture and 
the single enantiomers. 
2.2. Chemistry 
Only synthetic procedures followed to obtain compounds not previously characterized in 
literature are described in this paper. The synthesis of the racemic mixture and of the 
enantiomers of compound 8 is shown in Scheme 1. Ester (RS)-60 was obtained following 
Williamson reaction of (RS)-bromopropanoate, (RS)-58 with 2,6-dimethylphenol, while (R)- and 
(S)-61 were obtained by Mitsunobu reaction [34,35] of 2,6-dimethylphenol with (S)- or (R)-
methyl lactate [(S)- or (R)-59], respectively. After esters reduction, the obtained alcohols 61were 
submitted to Mitsunobu reaction with phthalimide to give the desired compounds. Compound 13 
was obtained through hydrolysis of compound 12 (Scheme 2). The synthesis of compounds (S)-
17, (S)- and (R)-33 is depicted in Scheme 3. (S)- and (R)-33 were obtained by protecting (S)- and 
(R)-2-amino-2-phenylethanol, respectively, with phthalic anhydride. Iodination of compound 
(S)-33 yielded compound (S)-17. Compounds 20 and 22 were synthesized as reported in Scheme 
4. Cyano derivative 18 was converted into the corresponding trimethyltintetrazole derivative 62 
by reaction with azido-trimethyltin. The treatment of compound 62 with gaseous HCl gave 
tetrazole derivative 22, which was alkylated with methyl iodide to give compound 20. 
Compound 24 was obtained by reacting 2-(methoxycarbonyl)benzoic acid with p-toluidine in 
presence of EEDQ as previously described (Scheme 5) [36]. The nitration of (R)-63, followed by 
reduction of the nitro group gave (R)-7 and, successively, (R)-43 (Scheme 6), as reported in the 
literature [26, 37, 38]. Compounds 25 and 55 were prepared by protecting 4-phenylbutan-1-
amine with phthalimide or tetrachlorophthalimide, respectively (Scheme 7). The synthesis of 
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compound 52 is reported in Scheme 8. 3-Aminopropanol aminopropanol was protected with 
phthalic anhydride to give compound 64, which was submitted to Mitsunobu reaction with 1-
naphthol. Compound 65 (Scheme 9) was synthesized by the reaction of 3-aminopropanol with 
tetrachlorophthalic anhydride and converted into compound 53. The synthesis of compound 54 is 
depicted in Scheme 10. Williamson reaction on 3-bromopropanol with thiophenol gave 
compound 67 which was converted into the thioether 55. Finally, the synthesis of (R)-1 was 
obtained via a Mitsunobu reaction starting from (S)-68 (Scheme 11).     
2.3. Biological evaluation of the compounds library 
The selected 56 compounds were tested against EfTS and hTS enzymes in order to evaluate the 
inhibitory activity towards TS and the specificity towards the bacterial enzyme (Table S1, Figure 
2, Table S1, see Supplementary Material). The percentage of inhibition (I %) at 100 µM are 
reported as heat-map plot in Figure 2 in which different colorcolor codes are based on the 
inhibition range of the compounds. Moreover, the inhibitory activity towards 
EcherichiaEscherichia coli TS (EcTS) was assessed, aiming to explore a larger biological 
activity profile. Several compounds of the library are chiral, thus they were tested as racemic 
mixture and/or as homochiral. Thirteen compounds (4, 7, 11, 18, 20, 23, 35, 39, 40, 45, 47, 52 
and 54) show inhibitory activity towards EfTS (I % = 20-60 % at 100 µM). Compounds 18, (R)-
40 and 54, with Ki of 25, 13 and 24 µM, respectively, turned out to be the best inhibitors of the 
library. Moreover, they were species-specific inhibitors of EfTS, since they were inactive at 100 
µM towards hTS. Few compounds (RS)-1, (R)-7, (R)-8, 9, 14, 16, 24, 25 were able to decrease 
the EcTS activity by 35-48 % at 100 µM and represent the most potent EcTS inhibitors of this 
set of compounds. In our previous paper [8], we studied the inhibitory activity towards EfTS of 
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more rigid phthalimide derivatives (6A, 8A, 12A, Figure 1). The phthalimide moiety had been 
directly connected to substituted aromatic or heteroaromatic rings in position 2. Compound 6A, 
8A and 12A showed a significant EfTS inhibitory activity, with compound 12A being the most 
active (Ki = 2.0 ± 0.35 μM). In the present study, we evaluated the activity of more flexible 
molecules. The spacer between the phthalimide moiety and the aromatic side chain was from 2 to 
10 carbons long (Figure 1, III). In most cases, an ether or a thioether spacer was used. If we 
compare the overall inhibitory activity of the previously published library with that of the present 
library, we can state that more rigid compounds are preferable with respect of flexible molecules, 
for EfTS binding. 
2.4. X-ray crystal structures of EfTS in complex with (S)-12 and with MTX 
X-ray crystallographic studies were carried out on structurally different N-substituted 
phthalimides. Overall, the present library showed medium to low affinity towards EfTS. All the 
compounds showing a percentage of inhibition towards EfTS of 10%-60% were selected for the 
crystallographic screening. From the screened crystals, we obtained usable diffraction data only 
for EfTS complexes with (R)-2, (S)-12 and 14. Unfortunately, the Fourier difference maps for 
(R)-2 and 14 complexes showed only blurred features corresponding to the bound inhibitor into 
the active site that prevented model building. In addition, we also obtained a dataset for EfTS 
bound by MTX (Ki = 13 µM) that has been used for comparison. Eventually, only the electron 
density for the (S)-12 inhibitor bound to EfTS was complete and confidently interpreted (PDB: 
4O7U) and compared with that of EfTS-MTX complex (PDB: 5J7W). MTX has a Ki equal to 
that of the best phtalimidic inhibitor of the series, compound (R)-40. The two independent EfTS 
dimers present in the crystal asymmetric unit of the EfTS-(S)-12 complex (Figure 3A) display 
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subunit heterogeneity: one subunit is empty and in the ‘open’ conformation [14], while the other 
one hosts the exogenous ligand and is in a ‘closed’ conformation (Figure 3B). The ‘open’ 
conformation is characterized by the loop 92-102 being open and mostly disordered and by the 
short helix 103-109 and the first two turns of helix 111-130 being completely unfolded. In the 
‘closed’ conformation the secondary structure elements described above are fully ordered with 
the loop closer to the active site cavity (see Figure 3B). Further heterogeneity is present in the 
‘closed’ subunits as they bind two different molecules into their active sites. We observed a 
mixture of two different complexes: 5-hydroxymethylene-6-hydrofolic acid (5-HMHF) is found 
in one dimer (Figure 4A), while the other dimer hosts the S-enantiomer of compound (RS)-12 
used for co-crystallization (Figure 4B). Subunit heterogeneity and half-site reactivity is 
commonly found in TS enzymes [39-41]. The electron density present in the active site of the B 
subunit led to identify the folate analogue as 5-hydroxymethylene-6-hydrofolate molecule (5-
HMHF), thus different from the 5-formyltetrahydrofolate (5-FTHF) already published [14]. The 
active site cavity of the B subunit shows electron density above noise, which is consistent with 
the planar structure of the pteridine moiety and in contrast with the puckered pyrazine ring of 
tetrahydrofolate found in our previous crystal structure of EfTS14 [14] (Figure 4A). The 
remaining parts of the molecule establish interactions similar to those of 5-FTHF. We have 
previously shown that EfTS obtained from our preparations contains bound metabolites from the 
folate pathway, such as 5-formyl-tetrahydrofolate (5-FTHF; PDB: 3UWl) [14]. 5-HMHF is a 
product of the conversion of 5-FTHF by bacterial enzymes (e.g. 5,10-methenyl-tetrahydrofolate 
synthetase enzyme). In fact, 5-HMHF was discovered for the first time bound to 5,10-methenyl-
tetrahydrofolate synthetase from Mycoplasma pneumoniae (PDB 1U3G) [42]. Analyzing the 
binding mode of (S)-12, we can suggest that this compound displaces 5-HMHF (or other folate 
Formattato: Non Evidenziato
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structural analogues), at least partially, from EfTS active site. This finding provides structural 
evidence of the competitive inhibition pattern of compound (S)-12 with respect to MTHF. The 
orientation of compound (S)-12 into EfTS active site is similar to that of 5-FTHF and 5-HMHF 
(Figure 4A-B). Compound (S)-12 establishes interactions with the hydrophobic residues 
surrounding the active site (Ile80, Trp81, Trp84, Leu194, Cys197, Leu223, Phe227, Tyr260 and 
Ile313). Only one hydrogen bond between the carbonyl group of compound (S)-12 and a water 
molecule is formed. The phthalimide core of compound (S)-12 places itself in the same position 
occupied by the pteridine moiety of the 5-HMHF and the para-substituted aromatic chain 
replaces the PABA moiety of 5-HMHF. The phthalimide core is wrapped in a lipophilic binding 
site and interacts with Leu194, Trp84 and Trp81, typical residues involved in the cofactor 
binding. The aromatic side chain has contact distance from the side chains of Glu59 (3.4 Å), 
Trp84 (3.1 Å) and Phe227 (3.4Å), while the acetoxy substituent in para position of the phenyl 
ring is at 3.7 Å from Leu223. In addition, the acetoxy group is located within 6.0 - 7.0 Å from 
several carbonyl groups of the main chain and from the backbone chains of Lys49 and Lys310. 
The absence of direct H-bonds and the prevalence of lipophilic interactions explain the low 
affinity of the compound for EfTS. Compound (S)-12 was the only compound of the series 
providing a crystal structure of its complex with EfTS despite (S)-12 is a weak inhibitor (10% at 
100 µM). This occurThis occurs frequently when hits screenings are performed to identify X-ray 
crystal structures needed to start a structure-based drug design [43]. The puzzling aspect of our 
EfTS is that, despite the addition of the dUMP to the crystallization medium, the substrate has 
never been found bound to the active site. A structural comparison between our enzyme and 
other bacterial TS that form ternary complexes with dUMP and folate analogues (e.g. PDB: 
1NCE) [41, 44] highlighted that 5-HMHF and (S)-12 are bound closer to EfTS catalytic Cys197 
Formattato: Non Evidenziato
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where usually dUMP binds, if compared to the folate analogues. However, a slight 
rearrangement of the cofactor could be expected to allow space for dUMP binding. Probably, the 
sulfate anions used at high concentration for crystallization compete for the same site where the 
phosphate group of dUMP binds [14]. 14 Indeed, a sulfate anion is bound in the active site cavity 
at the same site in all subunits. This site corresponds to the binding site of the dUMP phosphate 
group in 1NCE as well as other E. coli TS complexes with dUMP and the inhibitors F9 (PDB: 
4LRR) [10] or BGC 945 (PDB: 4ISK) [45, 46]. In our previous paper [8] the crystallographic 
complexes of LcTS with phthalimidic compounds (I in Figure 1) have been obtained. Due to the 
structural similarity between LcTS and EfTS, we can compare the complexes of LcTS-inhibitors 
already published [8] with the complex EfTS-(S)-12. The compounds of the previously published 
library presented a phthalimide core directly linked to the side chain, thus they cannot assume a 
folded conformation and they show a binding mode different to that of compound (S)-12. 
Moreover, the presence of dUMP in LcTS complexes suggested that dUMP induces a different 
orientation of the phtalimidic core into TS active site and contributes to stabilize the protein-
ligand complex interaction. On the other hand, the compounds of the present paper have spacers 
between the phthalimide core and the aromatic moiety, therefore only a folded conformation is 
possible for binding into EfTS active site; the obtained results suggest that this decreases the 
inhibition activity and complex stability. The structure determination of EfTS complexes with 
rigid inhibitors (e.g. 6A, 8A and 12A) could further clarify the potential of phthalimide 
derivatives as tool for the EfTS inhibition. The structure of EfTS-MTX shows the same subunit 
heterogeneity observed for the EfTS-(S)-12 complex with two subunits (A and B) in “open” 
conformation and two in “closed” conformation with the MTX inhibitor bound. At variance with 
the previous structure, no 5-HMHF is found, possibly suggesting that MTX has replaced the 
Formattato: Non Evidenziato
 12
folate derivative in both subunits. The pose and the electron density of MTX bound to EfTS is 
reported in Figure 5A and compared with the EfTS-(S)-12 in Figure 5B. (S)-12 and MTX assume 
essentially the same pose in the EfTS active site and make similar interactions. The glutamic acid 
moiety terminal portion of MTX, that is missing in (S)-12, does not interact with the cavity, the 
closest approach being that of the vicinal carboxylate group of MTX lying at 3.4 Å  and 4.0 Å 
from the side chains of Phe227 and Lys48, respectively. It is noteworthy that, as for the (S)-12 
EfTS structure, dUMP is not bound into the active site of the EfTS-MTX complex and the 
binding site of dUMP phosphate is occupied by a sulfate anion in both crystal structures. 
Comparison of the EfTS-(S)-12 and MTX structures with the closed form of human TS with 
bound raltitrexed (PDB: 1HVY) suggests a possible way to increase specificity and affinity of 
inhibitors towards the bacterial enzyme. The only relevant difference between human TS and 
EfTS cavity consists in the presence of Glu88 that is replaced by Ala111 in the human enzyme. 
The side chain of Glu88 is located at about 7.0 Å from the dimethyl benzene ring of (S)-12 and 
from the PABA ring of MTX. The design and synthesis of (S)-12 derivatives where the benzene 
ring bears meta substituents able to form H-bonds with the side chain of Glu88 could lead to an 
increased affinity towards EfTS together with specificity. 
 
3. Conclusions 
Aiming to obtain novel specific inhibitors of EfTS enzyme, we combined an in vitro target-based 
screening approach with X-ray crystallographic studies. The most interesting compounds (18, 
(R)-40 and 54) showed Ki of 13-25 µM, with compound (R)-40 being the most potent and 
selective towards EfTS with respect to the human enzyme. X-ray crystallographic studies were 
carried out on structurally different phthalimides. The X-ray crystal structure of EfTS in complex 
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with a low affinity inhibitor, (S)-12, was determined and refined. In this structure EfTS behaves 
as half-site enzyme According to the crystallographic structure, compound (S)-12 binds into the 
active site with an orientation analogue to that of folate metabolites, thus suggesting a 
competitive behavior with respect to the folate co-substrate. One subunit binds a folate 
metabolite (5-HMHF), suggesting that high affinity ligands are needed to fully displace the 
substrates in both the subunits. We can conclude that target druggability is affected by the 
presence of folate analogues bound into one EfTS subunit. Moreover, we solved the X-ray 
crystal structure of EfTS in complex with MTX (Ki = 13 µM) in which the folate metabolites, 
such as 5-HMHF, are not bound. This confirms the ability of high affinity ligands to displace the 
metabolites from the binding site. The present study discloses the EfTS druggability and 
represents an interesting starting point for a target-based drug design aimed at developing more 
potent EfTS inhibitors and antibacterial drugs.  
Appendix A. Supplementary data 
Supplementary data related to this article can be found at  
 
 
4. Experimental section 
4.1. Chemistry. The synthesis of compounds 1,4,10,21,23 [19], 2,12,42,50 [21, 22], 3,6,41 [23, 
24], 5,27–32,56 [25], 9,11,14–16,26,35,44–49,65 [27], 18 [29], 19 [47], 34 [30], 36–40,51 [18], 
63 [31, 32] has been already published in literature. For compound 7, only the (R)-enantiomer, 
not previously reported, has been herein described, while (RS)-7 is described in the literature 
[26]. Compounds 22, 24, 25, 52, 55 had been previously described in the literature (as referenced 
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below) but not fully characterized and/or synthesized following different procedures. All 
chemicals were purchased from Sigma-Aldrich or Lancaster in the commercially available 
highest quality. Solvents were reagent grade unless otherwise indicated. Yields refer to purified 
products and were not optimized (Table S4, see Supplementary Material). The structures of the 
compounds were confirmed by routine spectrometric analyses. Only spectra for compounds not 
previously described are given. Melting points (mp) were determined on a Gallenkamp melting 
point apparatus in open glass capillary tubes and are uncorrected (Table S4, see Supplementary 
Material). The infrared spectra were recorded on a Perkin-Elmer SpectrumOne FT 
spectrophotometer and band positions are given in reciprocal centimetres (cm–1). 1H NMR and 
13C NMR spectra were recorded on a Varian VX Mercury spectrometer operating at 300 and 75 
MHz for 1H and 13C, respectively, using CDCl3 and DMSO-d6 as solvents. Chemical shifts are 
reported in parts per million (ppm) relative to solvent resonance: CDCl3, δ 7.26 (1H NMR) and δ 
77.3 (13C NMR); DMSO-d6, δ 2.48 (1H NMR). J values are given in Hz (NMR Spectra for 
compounds 2, 3, 5, 6, 9, 11, 12, 14, 16, 18, 36-42, 44-50 are available in the Supplementary 
Material.). Gas chromatography (GC)/mass spectroscopy (MS) was performed on a Hewlett-
Packard 6890–5973 MSD at low resolution. Liquid chromatography (LC)/mass spectroscopy 
(MS) was performed on a spectrometer Agilent 1100 series LC-MSD Trap System VL. The 
molecular ion was designed as “M+”. Elemental analyses were performed on a Eurovector Euro 
EA 3000 analyzer and the data for C, H, N were within ± 0.4 of theoretical values (Table S3, see 
Supplementary Material). Optical rotations were measured on a Perkin Elmer (Norwalk, CT) 
Mod 341 spectropolarimeter; concentrations are expressed in g/100 mL, and the cell length was 
1 dm, thus [α]D21 values are given in units of 10–1 deg  cm2 g–1. Chromatographic separations 
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were performed on silica gel columns by flash chromatography (Kieselgel 60, 0.040 – 0.063 mm, 
Merck, Darmstadt, Germany) as previously described [48, 49]. 
4.1.1. (R)-2-[1-Methyl-2-(1-naphthyloxy)ethyl]-1H-isoindole-1,3(2H)-dione (R)-1. Prepared 
as reported below for (RS)-8 starting from (S)-68 and phthalimide. Yield: 57%; mp 79–81 °C 
(EtOAc/hexane); [α]20D = –38 (c 1, CHCl3). Spectroscopic and spectrometric data were in 
agreement with those found in the literature for the racemate [19]. Anal. Anal.Calcd. for 
C21H17NO3 %: C, 76.12; H 5.17; N 4.23. Found: C, 75.85; H 5.16; N 4.31. 
(R)-2-[2-(2,6-Dimethyl-4-nitrophenoxy)-1-methylethyl]-1H-isoindole-1,3(2H)-dione (R)-7. 
0.65 g (2.1 mmol) of (R)-63 were dissolved in 5 mL of trifluoroacetic acid at room temperature. 
Then, 0.22 g (2.5 mmol) of sodium nitrate were added to the solution in small portions during the 
period of 60 min. The mixture was stirred overnight, then diluted with 15 mL of diethyl ether 
and 3 mL of brine. The aqueous phase was extracted with Et2O for three times. The organic 
layers, washed with 20 % NaOH aqueous solution, were dried over anhydrous Na2SO4 to give 
0.65 g (85%) of an orange foam which was recrystallized from Et2O/petroleum ether to give 
orange crystals: mp 105–106 °C (Et2O/petroleum ether); [α]20D = –30 (c 2, CHCl3); 1H NMR 
(CDCl3): δ 1.55 (d, J = 7.2 Hz, 3H, CH3CH), 2.26 (s, 6H, CH3), 3.96 (dd, J = 9.3, 5.5 Hz, 
CHHCH), 4.48 (t, J = 9.3 Hz, 1H, CHHCH), 4.80–4.95 (m, 1H, CH), 7.70–7.76 (m, 2H, ArHC-
5,6), 7.82–8.00 (m, 4H, ArOHC-3,5, ArHC-4,7). Other spectroscopic data were in agreement 
with those reported in the literature for the racemate [26]. Anal. calcd for C19H18N2O5 %: C, 
64.40; H 5.12; N 7.91. Found: C, 64.45; H 5.16; N 7.95. 
(RS)-2-[2-(2,6-Dimethylphenoxy)propyl]-1H-isoindole-1,3(2H)-dione (RS)-8. To a stirred 
solution of (RS)-61 (1.97 g, 10.9 mmol), phthalimide (2.40 g, 16.3 mmol) and 
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triphenylphosphine (4.28 g, 16.3 mmol) in dry THF (100 mL), under N2 atmosphere, a solution 
of diisopropylazodicarboxylate (DIAD) (3.30 g, 16.3 mmol) in dry THF (50 ml) was added 
dropwise. The mixture was stirred at room temperature for 24 h. The solvent was then 
evaporated under reduced pressure, Et2O was added and the precipitate formed was filtered off. 
The filtrate was evaporated in vacuovacuum and the residue was purified by flash 
chromatography (eluent EtOAc/petroleum ether 2:8) to give 3.24 g of a white solid (96 %) which 
was recrystallized from EtOAc: mp 90–91 °C; IR (KBr): 1772, 1717 (C=O) cm–1; 1H NMR 
(CDCl3): δ 1.19 (d, J = 6.0 Hz, 3H, CH3CH), 2.22 (s, 6H, CH3Ar), 3.85 (dd, J = 13.5, 6.3 Hz, 
1H, CHH), 4.07 (dd, J = 13.6, 7.0 Hz, 1H, CHH), 4.52 (sextet, J = 6.3 Hz, 1H, CH),  6.82–7.0 
(m,3H, Ar), 7.68–7.78 (m, 2H, Ar), 7.82–7.90 (m, 2H, Ar); 13C NMR (CDCl3):δ 17.3 (2C), 18.2 
(1C), 43.4 (1C), 74.2 (1C), 123.5 (2C), 123.7 (1C), 129.2 (2C), 131.4 (2C), 132.2 (2C), 134.2 
(2C), 153.1 (1C), 168.5 (2C); GC/MS (70 eV) m/z (%) 309 (M+, 16), 188 (100). Anal. Anal. 
calcd for C19H19NO3.0.25H2O %: C, 72.71; H 6.26; N 4.46. Found: C, 72.85; H 6.19; N 4.51. 
(R)-2-[2-(2,6-Dimethylphenoxy)propyl]-1H-isoindole-1,3(2H)-dione (R)-8. Prepared as 
reported above for (RS)-8 starting from (R)-61. Yield: 87 %; white crystals: mp 69–70 °C 
(EtOAc); [α]20D = –81 (c 2, CHCl3). Spectroscopic data were in agreement with the racemate. 
Anal. Anal. calcd for C19H19NO3 %: C, 73.77; H 6.19; N 4.53. Found: C, 73.82; H 6.24; N 4.57. 
(S)-2-[2-(2,6-Dimethylphenoxy)propyl]-1H-isoindole-1,3(2H)-dione (S)-8. Prepared as 
reported above for (RS)-8 starting from (S)-61. Yield: 80 %; white crystals: mp 70–71 °C 
(EtOAc); [α]20D = +79 (c 2, CHCl3). Spectroscopic data were in agreement with the racemate. 
Anal.  calcd for C19H19NO3 %: C, 73.77; H 6.19; N 4.53. Found: C, 73.59; H 6.18; N 4.57. 
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2-[1-(4-Hydroxy-2,6-dimethylphenoxy)propan-2-yl]-1H-isoindole-1,3(2H)-dione (RS)-13. A 
solution of (RS)-12 (0.82 g, 2.23 mmol) in THF (6 mL) and 10 % HCl solution (5 mL) was 
stirred in an ice-bath for 3 h. Then the mixture was stirred at room temperature for 48 h. The 
solvent was evaporated under vacuum and extracted with EtOAc. The organic layer was dried 
(Na2SO4) to give a slightly yellowish solid which was recrystallized from EtOAc/petroleum ether 
to give 0.43 g (59 %) of slightly yellowish crystals: mp 178–179 °C; IR (KBr): 3412 (OH), 1770, 
1699 (C=O); 1H NMR (CDCl3): δ 1.53 (d, J = 6.9 Hz, 3H, CH3CH), 2.12 (s, 6H, CH3Ar), 3.84 
(dd, J = 9.2, 5.6 Hz, 1H, CHHCH), 4.29 (t, J = 9.2 Hz, 1H, CHHCH), 4.58 (br s, 1H, OH), 4.76–
4.92 (m, 1H, CH), 6.41 (s, 2H, Ar), 7.65–7.74 (m, 2H, Ar), 7.78–7.90 (m, 2H, Ar); 13C NMR 
(CDCl3): δ15.4 (1C), 16.5 (2C), 47.4 (1C), 72.2 (1C), 115.2 (2C), 123.4 (2C), 132.1 (2C), 132.2 
(2C), 134.2 (2C), 149.3 (1C), 151.5 (1C), 168.7 (2C); GC/MS (70 eV) m/z (%) 325 (M+, 5), 188 
(100). Anal. Anal. calcd for C19H19NO4.0.20H2O %: C, 69.37; H 5.94; N 4.26. Found: C, 69.59; 
H 5.84; N 4.37. 
(S)-2-(2-Iodo-1-phenylethyl)-1H-isoindole-1,3(2H)-dione (S)-17. Into a stirred ice-cooled 
solution of (S)-33 (1.74 g, 6.5 mmol) in dry toluene (30 mL) under N2 atmosphere, HI was 
bubbled until saturation occurred. The mixture was stirred at −5 °C for 1 h and at room 
temperature for 48 h. The solvent was then evaporated under vacuum and the residue, taken up 
with EtOAc, was washed with 6 N NaOH, 2 N HCl, and brine. The organic layer was dried 
(Na2SO4) and concentrated under vacuum to give 1.7 g (70 %) of a slightly yellowish solid 
which was recrystallized from MeOH to give (S)-17 as white crystals: mp 123–124 °C; [α]20D = 
–16 (c 2, CHCl3); IR (KBr): 1780, 1707 (C=O); 1H NMR (CDCl3): δ 3.83 (dd, 1H, J = 10.5, 5.2 
Hz, CHH), 4.53 (t, 1H, J = 10.8 Hz,CH), 5.56 (q, 1H, J = 5.2 Hz, CHH), 7.28–7.38 (m, 3H, Ar), 
7.50–7.58 (m, 2H, Ar), 7.68–7.76 (m, 2H, Ar), 7.82–7.88 (m, 2H, Ar); 13C NMR (CDCl3): δ 4.8 
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(1C), 57.8 (1C), 123.8 (2C), 128.1 (2C), 128.9 (2C), 129.2 (1C), 131.8 (2C), 134.5 (1C), 138.1 
(2C), 168.1 (2C); GC/MS (70 eV) m/z (%) 377 (M+, <1), 250 (100). Anal. Anal. calcd for 
C16H12NO2I %: C, 50.95; H 3.21; N 3.71. Found: C, 51.15; H 3.25; N 3.79. 
2-{[2'-(1-Methyl-1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-isoindole-1,3(2H)-dione 20. 
Potassium carbonate (65.2 g, 0.47 mmol) was added to a solution of 22 (0.15 g, 0.39 mmol) in 10 
mL of acetone. The mixture was stirred at room temperature for 30 min, and then methyl iodide 
(0.11 g, 0.77 mmol) was added. The reaction mixture was refluxed for 2h. After cooling, the 
reaction mixture was filtered and evaporated. The residue was extracted with EtOAc and washed 
twice with H2O. After drying (Na2SO4), the organic phase was evaporated to afford a crude solid 
which was purified by crystallization from CHCl3/hexane affording 83 mg (54 %) of white 
crystals: mp 210–211 °C; IR (KBr): 1766, 1705 (C=O); 1H NMR (CDCl3):δ 4.22 (s, 3H, CH3), 
4.82 (s, 2H, CH2), 7.04–7.16 (m, 2H, Ar), 7.28–7.38 (m, 2H, Ar), 7.40–7.90 (m, 8H, Ar); 13C 
NMR (CDCl3): δ 33.8 (1C), 41.3 (2C), 122.6 (1C), 123.6 (2C), 123.7 (1C), 128.2 (1C), 128.4 
(2C), 129.1 (1C), 130.6 (2C), 131.7 (1C), 132.0 (1C), 134.3 (2C), 135.3 (1C), 136.6 (1C), 138.7 
(1C), 141.5 (1C), 168.3 (2C); GC/MS (70 eV) m/z (%) 395 (M+, 34), 394 (100). Anal. Anal. 
calcd for C23H17N5O2 %: C, 69.86; H 4.33; N 17.71. Found: C, 69.47; H 4.37; N 17.43. 
2-{[2'-(1H-Tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-isoindole-1,3(2H)-dione 22. A suspension 
of compound 62 (0.60 g, 1.1 mmol) in a mixture of toluene (8 mL) and THF (2 mL) was stirred 
in an ice bath. Gaseous HCl was then added to give a clear solution followed by precipitation of 
the desired product. The precipitate was filtered, and the filtrate was washed with toluene to give 
a white solid (0.40 g, 96 %): mp: >250 °C; IR (KBr): 3458 (NH), 1767, 1714 (C=O), 1463, 1252 
(N-N=N) cm–1; 1H NMR (DMSO-d6): δ 4.72 (s, 2H, CH2), 7.04 (d, J = 8.2 Hz, 2H, Ar), 7.23 (d, 
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J = 8.2 Hz, 2H, Ar), 7.46–7.70 (m, 4H, Ar), 7.78–7.96 (m, 4H, Ar), 16.4 (1H, NH); LC/MS m/z 
380 [M+ – 1]. Other spectroscopic data were in agreement with the literature [50]. Anal. Anal. 
calcd for C22H15N5O2.0.50H2O %: C, 67.68; H 4.13; N 17.94. Found: C, 67.73; H 4.03; N 17.70. 
2-(4-Methylphenyl)-1H-isoindole-1,3(2H)-dione 24. EEDQ (1.48 g, 6 mmol), p-toluidine (0.59 
g, 5.5 mmol) and Et3N (1.04 mL, 7.5 mmol) were successively added to a stirring solution of  2-
(methoxycarbonyl)benzoic acid (1.0 g, 5 mmol) in CHCl3 (160 mL). The reaction mixture was 
heated under reflux for 6 h. The solvent was removed under reduced pressure and the residue, 
taken up with EtOAc, was washed three times with 2 N HCl, twice with 2 N NaOH, and then 
dried over anhydrous Na2SO4. The organic phase was evaporated to afford a crude solid which 
was purified by crystallization from CHCl3/hexane to give 0.90 g (67 %) of 24 as beige crystals: 
mp 205–206 °C; IR (KBr): 1747, 1716 (C=O); 1H NMR (CDCl3):δ 2.41 (s, 3H, CH3), 7.31 (s, 
4H, Ar), 7.74–7.82 (m, 2H, Ar), 7.92–7.99 (m, 2H, Ar); GC/MS (70 eV) m/z (%) 237 (M+, 100). 
Other spectroscopic data were in agreement with the literature [51]. Anal. Anal. calcd. for 
C15H11NO2.0.20H2O %: C, 74.80; H 4.77; N 5.82. Found: C, 75.06; H 5.08; N 6.00. 
2-(4-Phenylbutyl)-1H-isoindole-1,3(2H)-dione 25. Prepared as reported for compound 55 
starting from 4-phenylbutan-1-amine and phthalic anhydride. Yield: 62 %; white solid: mp 84–
85 °C. Spectroscopic data were in agreement with the literature [52]. 
(R)-2-(2-Hydroxy-1-phenylethyl)-1H-isoindole-1,3(2H)-dione (R)-33. Prepared as reported 
above for compound 64 starting from (R)-phenylglycinol and phthalic anhydride. Yield: 88 %; 
white crystals: [α]20D = + 41 (c 2, CHCl3); IR (neat): 3464 (OH), 1772, 1710 (C=O); 1H NMR 
(CDCl3): δ 2.64 (br s, 1H, OH), 4.21 (dd, J = 11.6, 5.0 Hz, 1H, CHH), 4.65 (dd, J = 11.6, 9.3 Hz, 
1H, CHH), 5.41–5.53 (m, 1H, CH), 7.23–7.38 (m, 3H, Ar), 7.40–7.50 (m, 2H, Ar), 7.63–7.73 
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(m, 2H, Ar), 7.74–7.85 (m, 2H, Ar). Other spectroscopic data were in agreement with those 
reported in the literature [53,54]. Anal. Anal. calcd. for C16H13NO3 %: C, 71.90; H 4.90; N 5.24. 
Found: C, 72.24; H 4.99; N 5.40. 
(S)-2-(2-Hydroxy-1-phenylethyl)-1H-isoindole-1,3(2H)-dione (S)-33. Prepared as reported 
above for compound 64 starting from (S)-phenylglycinol and phthalic anhydride. Yield: 85 %; 
slightly yellowish crystals: [α]20D = –32 (c 2, CHCl3). Other spectroscopic data were in 
agreement with those reported in the literature for the R-enantiomer [53,54]. 
(R)-2-[1-(4-amino-2,6-dimethylphenoxy)propan-2-yl]-1H-isoindole-1,3(2H)-dione 
hydrochloride (R)-43.  Catalytic hydrogenation of (R)-7 (0.35 g, 1.0 mmol) in 10 mL of 
absolute EtOH was conducted at room temperature for 12 h in the presence of 10% palladium on 
carbon at 10 bar. The catalyst was filtered off and the solvent was removed under reduced 
pressure to give 0.23 g (70 %) of the free amine (R)-43 as a yellow oil which was converted into 
its hydrochloride salt by dissolving the free base in a small amount of aqueous 1N HCl and 
azeotropically removing water. The crude solid obtained was recrystallized from EtOH/Et2O: mp 
256–258 °C; [α]20D = –42 (c 2, MeOH). Spectroscopic and spectrometric data were in agreement 
with those found in the literature for the racemate [26]. Anal. Anal. calcd for 
C19H20N2O3.HCl.0.33H2O %: C, 62.21; H 5.95; N 7.64. Found: C, 62.16; H 6.06; N 7.24. 
 
2-[3-(Naphthalen-1-yloxy)propyl]-1H-isoindole-1,3(2H)-dione 52.  Prepared as reported 
above for (RS)-8 starting from (R)-64 and 1-naphthol using diethyl azodicarboxylate (DEAD) 
instead of DIAD. Yield: 36 %; mp 150–151 °C (EtOAc/hexane), lit [55] 154–154.5 °C; IR 
(KBr): 1765, 1713 (C=O) cm–1; 1H NMR (CDCl3): δ 2.34(quintet, J = 6.9 Hz, 2H, 
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CH2CH2CH2),4.01 (t, J = 6.8 Hz, 2H, CH2N),4.22 (t, J = 6.0 Hz, 2H, CH2O), 6.76 (d, J = 6.6 Hz, 
1H, Ar), 7.33–7.44 (m, 4H, Ar), 7.64–7.68 (m, 2H, Ar),7.75 (d, J = 8.2 Hz, 1H, ArO), 7.78–7.82 
(m, 2H, Ar),8.16 (d, J = 7.7, 1H, Ar); 13C NMR (CDCl3): δ 28.7 (1C), 35.9 (1C), 66.1 (1C), 
104.7 (1C), 120.6 (1C), 122.1 (1C), 123.4 (2C), 125.3 (1C),125.7 (1C), 126.0 (1C), 126.5 (1C), 
127.6 (1C), 132.4 (2C), 134.1 (2C), 134.6 (1C), 154.6 (1C), 168.6 (2C); GC/MS(70 eV) m/z (%) 
331 (M+, 13), 188 (100). 
4,5,6,7-Tetrachloro-2-(3-phenoxypropyl)-1H-isoindole-1,3(2H)-dione 53. Prepared as 
reported above for (RS)-8 starting from 65 and phenol using diethyl azodicarboxylate (DEAD) 
instead of DIAD. Yield: 30 %; mp 211–212 °C (EtOAc/hexane); IR (KBr): 1777, 1712 (C=O) 
cm–1; GC/MS (70 eV) m/z (%) 419 (M+, 6), 326 (100). Anal. calcd for C17H11Cl4NO3.0.50H2O 
%: C, 47.70; H 2.83; N 3.27. Found: C, 47.62; H 2.65; N 3.41. 
4,5,6,7-Tetrachloro-2-[3-(phenylsulfanyl)propyl]-1H-isoindole-1,3(2H)-dione 54. Prepared as 
reported above for (RS)-8 starting from 67 and tetrachlorophthalimide, using 
diethylazodicarboxylate (DEAD) instead of DIAD. Yield: 20 %; mp 140–141 °C 
(THF/petroleum ether); IR (KBr): 1775, 1713 (C=O) cm–1; 1H NMR (CDCl3): δ 1.97–2.04 (m, 
2H, CH2CH2CH2), 2.93 (t, J = 7.1 Hz, 2H, CH2S), 3.83 (t, J = 7.0 Hz, 2H, CH2N), 7.15–7.35 (m, 
5H, Ar); 13C NMR (CDCl3): δ 27.9 (1C), 31.7 (1C),38.1 (1C),126.7 (2C),127.8 (1C), 129.2 (2C), 
129.8 (2C), 130.3 (2C), 135.7 (2C),140.3 (1C), 163.7 (2C); GC/MS (70 eV) m/z (%) 433 (M+, 
54), 149 (100). 
4,5,6,7-Tetrachloro-2-(4-phenylbutyl)-1H-isoindole-1,3(2H)-dione 55. A mixture of 4-
phenylbutan-1-amine (2.0 g, 13.4 mmol), tetrachlorophthalic anhydride (3.83 g, 13.4 mmol), 
triethylamine (0.13 g, 1.34 mmol) in toluene (20 mL) was heated under reflux in a flask fitted 
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with a Dean–Stark tube for 7 h. During this period, the temperature of the oil bath is maintained 
at about 130 °C and water separates. All volatile matter were then evaporated under vacuum and 
the solid residue was taken up with EtOAc and washed with 2 N HCl, NaHCO3, and H2O. The 
organic phase was dried (Na2SO4) and concentrated under vacuum to give a white solid which 
was recrystallized from EtOAc/hexane to give 3.90 g (70 %) of white crystals: mp 119–120 °C. 
Other spectroscopic data were in agreement with the literature [52]. Anal. calcd for 
C18H13Cl4NO2 %: C, 51.83; H 3.14; N 3.36. Found: C, 51.71; H 3.13; N 3.44. 
(RS)-Ethyl 2-(2,6-dimethylphenoxy)propanoate (RS)-59. Sodium (0.38 g, 16.5 mmol) was 
added in small pieces to absolute EtOH (30 mL) and the mixture was heated at 70 °C. After 
completion of sodium dissolution, a solution of 2,6-dimethylphenol (2.0 g, 16.5 mmol) in 
absolute EtOH (15 mL) was added dropwise. After 30 min, a solution of (RS)-ethyl 2-
bromopropanoate [(RS)-57] (2.98 g, 16.5 mmol) in absolute EtOH (15 mL) was added dropwise 
and the mixture was heated at reflux for 5 h. The solid residue was filtered off, the solvent was 
evaporated in vacuovacuum and the residue was taken up with diethyl ether, washed with 2 N 
NaOH and dried (Na2SO4). Removal of the solvent under vacuum gave 3.11 g (85 %) of (RS)-59 
as a yellow oil: IR (neat): 1737 (C=O) cm–1; 1H NMR (CDCl3): δ 1.28 (t, 3H, J = 7.1 Hz, 
CH3CH2), 1.53 (d, 3H, J = 6.6 Hz, CH3CH), 2.28 (s, 6H, CH3Ar), 4.23 (q, 2H, J = 7.1 Hz, CH2), 
4.49 (q, 1H, J = 6.6 Hz, CH), 6.86–6.94 (m, 1H, Ar), 6.95–7.03 (m, 2H, Ar); 13C NMR (CDCl3): 
δ 14.4 (1C), 17.2 (2C), 18.7 (1C), 61.3 (1C), 77.1 (1C), 124.2 (1C), 129.3 (2C), 131.1 (2C), 
154.8 (1C), 172.3 (1C); GC/MS (70 eV) m/z (%) 222 (M+, 91), 149 (100). 
(R)-Methyl 2-(2,6-dimethylphenoxy)propanoate (R)-60. Prepared as reported above for (RS)-8 
starting from 2,6-dimethylphenol and ethyl (S)-(–)-lactate [(S)-58]. Yield: 72 %; slightly 
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yellowish oil:[α]20D = +40 (c 2.1, CHCl3). Spectroscopic data were in agreement with the (S)-
isomer.  
(S)-Methyl 2-(2,6-dimethylphenoxy)propanoate (S)-60. Prepared as reported above for (RS)-8 
starting from 2,6-dimethylphenol and methyl (R)-(+)-lactate [(R)-58]. Yield: 37 %; slightly 
yellowish oil: [α]20D = –39 (c 2.1, CHCl3);IR (neat): 1759 (C=O) cm–1; 1H NMR (CDCl3):δ 1.53 
(d, J = 6.9 Hz, 3H, CH3CH), 2.27 (s, 6H, CH3Ar), 3.78 (s, 3H, CH3O), 4.51 (q, J = 6.9 Hz, 1H, 
CH), 6.88–7.04 (m,3H, Ar); 13C NMR (CDCl3): δ 17.2 (2C), 18.7 (1C), 52.3 (1C), 77.0 (1C), 
124.2 (1C), 129.3 (2C), 131.1 (2C), 154.7 (1C), 172.7 (1C); GC-MS (70 eV) m/z (%) 208 (M+, 
1), 122 (100). 
(RS)-2-(2,6-Dimethylphenoxy)propan-1-ol (RS)-61. To a suspension of LiAlH4 (1.28 g, 33.7 
mmol) in dry THF (60 mL), a solution of (RS)-59 (3.74 g, 16.9 mmol) in dry THF (60 mL) under 
N2 atmosphere was added. The mixture was stirred under moderate reflux for 1 h and then at 
room temperature for 24 h. The reaction was quenched by the careful addition of cold water until 
the end of gas evolution. The residue was removed by filtration and the filtrate shaken with H2O. 
The aqueous phase was extracted several times with Et2O. The combined extracts were dried 
over Na2SO4 and the filtrate was concentrated under vacuum. Purification by flash 
chromatography (EtOAc/petroleum ether 1:9) gave 1.85 g (61 %) of (RS)-61 as a colorless oil: 
IR (neat): 3416 (OH) cm–1; 1H NMR (CDCl3): δ 1.17 (d, J = 6.3 Hz, 3H, CH3CH), 2.28 (s, 7H, 
CH3Ar + OH), 3.68–3.84 (m, 2H, CH2), 4.18–4.30 (m, 1H, CH), 6.87–6.95 (m, 1H, Ar), 7.01 (d, 
J = 3.8 Hz, 2H, Ar); 13C NMR (CDCl3):δ 16.4 (1C), 17.4 (2C), 67.1 (1C), 78.1 (1C), 123.8 (1C), 
129.3 (2C), 131.4 (2C), 154.0 (1C); GC/MS (70 eV) m/z (%) 180 (M+, 37), 122 (100). 
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(S)-2-(2,6-Dimethylphenoxy)propan-1-ol (S)-61. Prepared as reported above for (RS)-61 
starting from (S)-60. Yield: 66 %; colorless oil: [α]20D = +9.0 (c 2.1, CHCl3); IR (neat): 3401 
(OH) cm–1;1H NMR (CDCl3): δ 1.17 (d, J = 6.3 Hz, 3H, CH3CH), 2.21 (br s overlapping s at 
2.28 ppm, exch. D2O, 1H, OH), 2.28 (s overlapping br s at 2.21 ppm, 6H, CH3Ar), 3.68–3.84 (m, 
2H, CH2), 4.18–4.29 (m, 1H, CH), 6.88–6.96 (m,1H, Ar), 6.97–7.05 (m, 2H, Ar); 13C NMR 
(CDCl3):δ 16.4 (2C), 17.4 (1C), 67.1 (1C), 78.0 (1C), 123.8 (1C), 129.3 (2C), 131.4 (2C), 154.0 
(1C); GC/MS (70 eV) m/z (%) 180 (M+, 26), 122 (100). 
(R)-2-(2,6-Dimethylphenoxy)propan-1-ol (R)-61. Prepared as reported above for (RS)-61 
starting from (R)-60. Yield: 62 %; colorless oil: [α]20D = –9.1 (c 2.1, CHCl3). Spectroscopic data 
were in agreement with the (S)-isomer. 
2-{[2'-[1-(Trimethylstannyl)-1H-tetrazol-5-yl]biphenyl-4-yl}methyl]-1H-isoindole-1,3(2H)-
dione 62. A solution of compound 18 (1.50 g, 4.44 mmol) in dry toluene (75 mL) and 
azidotrimethyltin (1.0 g, 4.89 mmol) was kept at 110 °C under nitrogen atmosphere for 24 h. The 
precipitate was filtered off and washed with hot toluene to give compound 62 as a white solid 
(0.90 mg, 37 %): mp> 250 °C; IR (KBr): 1763, 1709 (C=O), 550 (Sn–N) cm–1;1H NMR 
(DMSO-d6): δ 0.32 (br s, 9H, (CH3)3Sn), 4.71 (s, 2H, CH2), 6.98 (d, J = 8.2 Hz, 2H, Ar), 7.16 (d, 
J = 9.3 Hz, 2H, Ar), 7.35–7.55 (m, 4H, Ar), 7.75–7.95 (m, 4H, Ar); LC-MS m/z (%) 568 [M+ + 
23]. 
4,5,6,7-Tetrachloro-2-(3-hydroxypropyl)-1H-isoindole-1,3(2H)-dione 65. Prepared as 
reported above for (R)-33, starting from 3-aminopropanol and tetrachlorophthalic anhydride. 
Yield:32 %; mp193–194 °C (EtOAc/hexane); IR (KBr): 3319 (OH), 1774, 1707 (C=O) cm–1; 1H 
NMR (CDCl3): δ 1.85–1.92 (m, 2H, CH2CH2CH2), 1.98 (br s, 1H, OH),3.64 (t, J = 5.8 Hz, 2H, 
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CH2N), 3.86 (t, J = 6.3 Hz, 2H, CH2O); 13C NMR (CDCl3): δ 31.1 (1C), 35.7 (1C), 59.5 
(1C),127.7 (2C), 129.9 (2C),140.4 (2C); 164.2 (2C); GC/MS(70 eV) m/z (%) 343 (M+, 24), 298 
(100). Anal. calcd for C11H17Cl4NO3.H2O %: C, 36.60; H 2.51; N 3.88. Found: C, 36.53; H 2.11; 
N 3.86. 
3-(Phenylsulfanyl)propan-1-ol 67. K2CO3 (0.32 g, 2.32 mmol) was added to a solution of 3-
bromopropanol (0.29 g, 2.11 mmol) in dry DMF (30 mL) under N2 atmosphere. The reaction 
mixture was heated at 130 °C and then a solution of thiophenol (0.26 g, 2.32 mmol) in 20 mL of 
dry DMF was added dropwise during a period of 3 h. The mixture was stirred at this temperature 
for 24 h. After evaporation of the solvent, the residue was taken up with EtOAc, washed with 2 
N NaOH, and then with brine. The organic phase was dried (Na2SO4) and concentrated under 
vacuum. The residue was purified by column chromatography on silica gel (EtOAc/petroleum 
ether 2:8) to give 0.36 g (69 %) of a yellow oil; IR (neat): 3356 (OH) cm–1; 1H NMR (CDCl3): 
δ1.83–1.92 (m, 3H, CH2CH2CH2 + OH), 3.03 (t, J = 7.15 Hz, 2H, CH2SAr), 3.75 (t, J = 6.1 Hz, 
2H, CH2OH), 7.14–7.36 (m, 5H, ArS); 13C NMR (CDCl3): δ 30.5 (1C), 31.9 (1C), 61.6 (1C), 
126.2 (1C), 129.1 (2C), 129.4 (2C), 136.5 (1C); GC/MS (70 eV) m/z (%) 168 (M+, 10), 110 
(100). 
4.2. Enzymology. The compounds were screened for their activity and their species-specificity 
against EcTS, EfTS, and hTS. EcTS, and hTS were purified as described [8]. EfTS [14] 14 was 
purified following the procedure used for EcTS. Enzyme kinetics experiments were conducted 
by chromogenic assay under standard conditions [8, 14]. The Km values, by curve-fitting to 
hyperbolic curves, of EcTS, EfTS, and hTS for MTHF were, respectively, 5.8 µM, 13.6 µM, and 
6.9 µM.  These data represent the mean of triplicate measurements; in a typical study, the 
 26
standard deviation of the data fell within ± 20 % of the mean. The apparent inhibition constant 
(Ki app, simply defined as Ki within the text) values were obtained from the linear least-squares 
fit of the residual activity as a function of inhibitor concentration, assuming a competitive 
inhibition [8]. In the inhibition assays, the reaction mixture was the same as in the TS standard 
assay. Stock solutions of each inhibitor were freshly prepared in dimethyl sulfoxide (DMSO) and 
stored at – 80 °C.  In the reaction mixture, the concentration of DMSO never exceeded 5 %. 
Each experiment was repeated at least three times and an individual measurement did not differ 
more than 20 % from the mean. 
4.3. Crystallization. Crystallization trials for EfTS were performed using the vapor diffusion 
sitting drop method [56] at 297 K. Crystal Screen, Crystal Screen II and Greed Screen 
Ammonium Sulfate from Hampton Research were used for screening crystallization conditions. 
Drops consisting of 2 µL precipitant and 1 µL EfTS solution (7.8 mg/mL in 25 mM 
KH2PO4/K2HPO4  pH 6.8, 40 mM dUMP, 1 mM EDTA) were equilibrated against 100 µL 
reservoir solution. After one month crystals were observed into a drop containing 3.2 M 
ammonium sulfate and 0.1 M HEPES buffer, pH 7.0 as precipitant solution. These crystals were 
ill-formed and provided a poor diffraction pattern when exposed to X-ray radiation, therefore we 
tried to improve the crystal ordering/quality by applying seeding techniques56 The crystals 
obtained were crushed and seeding solutions were prepared by dilution with the successful 
precipitant solution (3.2 M ammonium sulfate and 0.1 M HEPES buffer, pH 7.0). 4 µL drops of a 
2.5 mg/mL EfTS solution (buffer 25 mM KH2PO4/K2HPO4 pH 6.8, 40 mM dUMP, 1 mM 
EDTA) were mixed with 2 µL of a precipitant solution containing 2.7 M ammonium sulfate and 
0.1 M HEPES buffer, pH 7.0. Streak-seeding has been performed at different dilution of the 
seeding solution. Drops were allowed to equilibrate at room temperature over 0.6 mL precipitant 
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solution in the well. Crystals suitable for diffraction appeared in 2-3 weeks into the drops in 
which a seeding solution diluted 1:100 was applied. Co-crystallization trials were performed also 
for the complexes EfTS- inhibitor using the same precipitant solution identified in the previous 
screen for the enzyme (3.2 M ammonium sulfate and 0.1 M HEPES buffer, pH 7.0). Trials of co-
crystallization were performed at 297 K using both the microbatch-under-oil crystallization 
technique [57, 58] with a 1:1 mixture of paraffin and silicon oil (Hampton Research) as well as 
the sitting-drop vapor-diffusion method. Because of the low solubility in water, concentrated 
solutions of each inhibitor were prepared in DMSO. A 4 mM solution of each inhibitor in DMSO 
has been added in a 1:10 volume ratio to a 6.5mg/mL EfTS solution (buffer 25 mM 
KH2PO4/K2HPO4  pH 6.8, 40mM dUMP, 1 mM EDTA). Drops have been prepared by mixing 2 
µL of the EfTS-inhibitor solution with 1 µL of a precipitant solution containing 3.2 M 
ammonium sulfate and 0.1 M HEPES buffer, pH 7.0. Crystals of EfTS complexes with the 
library molecules have been finally obtained using the microbatch-under-oil crystallization 
technique. As it can be appreciated from the above description, the crystallization screen has 
been extremely difficult and was a cumbersome process, rich of failures. Under the microscope, 
all the crystals obtained presented defects like cracks and lines indicating internal disorder. 
Before data collection, crystals were transferred to a cryoprotectant solution containing 20% 
ethylene glycol and 80% precipitant solution (2.7 M ammonium sulfate and 0.1 M HEPES pH 
7.0) and then flash frozen in liquid nitrogen. 
4.4. Structure solution and refinement. About 70 crystals were screened for diffraction at the 
ESRF (European Synchrotron Radiation Facilities) beamline ID29-1. The data collection 
demonstrated that all crystals were characterized by severe splitting and suffered from radiation 
damage, with the diffraction pattern decaying after about 100 seconds of exposure to X-rays 
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(0.5° oscillation images). Finally, we were able to obtain usable datasets referring to (R)-2, (S)-
12, 14 and MTX complexes. However, all of them were complete to a maximum of about 75-80 
%, but the missing data were randomly distributed in reciprocal space without jeopardizing the 
quality of the electron density maps [46]. Intensities were integrated using the program Mosflm 
[59] and scaled with the program Scala [60] or Aimless from the CCP4 Suite [61]. Data 
collection statistics are reported in Table S2 (see Supplementary Material). All EfTS crystals 
belong to space group P21 with four EfTS subunits in the asymmetric unit. The structures were 
solved by molecular replacement technique as implemented in the software MolRep [62] from 
the CCP4 Suite [61] using the crystal structure of Lactobacillus casei TS as model (PDB: 
2TDM; 73 % sequence homology). Because of the structural flexibility that characterize some 
domains of TS enzymes the LcTS loop 82-144 was removed from the model. Molrep provided 
the correct solution that consists of a couple of EfTS homodimers in the crystal asymmetric unit 
(A-B and C-D). The EfTS molecule was manually rebuilt in the electron density maps. The 
whole polypeptide chain could be completely reconstructed in only in the subunits were the 
inhibitor was bound. The unbound subunits presented disorder in the regions corresponding to 
residues 81-132 that were not clearly visible in the electron density maps and could be only 
partially built.  The Fourier difference maps showed electron density interpretable with the 
presence of the inhibitor only for EfTS-(S)-12, and EfTS-MTX complexes. The final models 
were refined using the program Refmac5 [63] from the CCP4 Suite.  Water molecules have been 
added using the program ArpWARP [64] and checked manually. The diffraction pattern of the 
crystals presented splitted reflections due to the lattice disordering as described above. This 
resulted in medium quality indicators of the refinement as shown in Table S2 (see 
Supplementary Materiairal). Nevertheless, the electron density maps were quite well defined and 
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could be confidently interpreted, as can be judged from the reported figures. The stereochemical 
quality of the final model was checked using the programs PROCHECK [65] and COOT [66]. 
The program COOT was also used for molecular modeling and to superimpose structures. 
Structural models were rendered using CCP4MG [67]. Atomic coordinates and structure factors 
for EfTS-(S)-12, and EfTS-MTX complexes have been deposited in the Protein Data Bank 
(PDB), www.rcsb.org, under the accession codes 4O7U and 5J7W, respectively. 
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Figure Legends 
 
Figure 1. Chemical structure of TS inhibitors and the prodrug 5FU. 
 
Figure 2. Inhibitory activity of compounds 1-56 against EfTS, hTS and EcTS. The compound 
activity is given as % of inhibition at 100 µM. Color code: dark green (values between 100 and 
35), light green (values between 34 and 10), yellow (values lower than 10), red (no detectable 
inhibition at 100 µM) and light blue (not tested). a MTX is the reference compound. Ki EfTS = 13 
µM. 
 
Figure 3. EfTS x-ray crystallographic structure. (A) The EfTS crystal asymmetric unit content. 
The two subunits of each heterodimer differ in the conformation of the small domain due to the 
presence of a ligand bound to the active site cavities. The subunit having a ligand bound are in 
closed conformation, while the unbound subunits are on open conformation. (B) comparison of 
closed and open conformations by superimposing subunit A (open; light blue ribbon) and B 
(closed; gold ribbon) of 4O7U. The 5-HMHF molecule is represented to show the position of the 
active site cavity. 
 
Figure 4. Detailed view of the binding ligands. (A) Stick representation of the (S)-12 inhibitor 
(yellow) bound to EfTS with superimposed the 2Fo-Fc electron density map at 1.3 σ (blue wire), 
computed with  refined phases and the omit map (green wire) contoured at 3.0 σ. Cys197 is also 
shown as sticks together with other relevant residues in the active site cavity. (B) Stick 
representation of 5-HMHF (yellow) bound to EfTS with superimposed the 2Fo-Fc electron 
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density map at 1.3 σ (blue wire), computed with refined phases and the omit map (green wire) 
contoured at 3.0 σ. Cys197 is also shown as sticks together with other relevant residues in the 
active site cavity. Notice the different extent of the omit map in the PABA moiety of 5-HMHF 
with respect to the same region in Figure 4A. 
 
Figure 5. The binding of MTX to EfTS. (A) Stick representation of the MTX inhibitor (yellow) 
bound to EfTS with superimposed the 2Fo-Fc electron density map at 1.3 σ (blue wire), 
computed with  refined phases and the omit map (green wire) contoured at 3.0 σ. Cys197 is also 
shown as sticks together with other relevant residues in the active site cavity. (B) Least-squares 
superimposition of MTX (green sticks) and (S)-12 (yellow sticks) bound to EfTS. Notice the 
similarity of the pose. 
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Figure 4. 
 
 
Figure 5. 
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Scheme 1. Reagents and conditions: (i) 2,6-dimethyphenol, Na, abs EtOH, 70°C, for (RS)-59; 
(ii) 2,6-dimethylphenol, PPh3, DIAD, dry THF, rt, for (R)- and (S)-60; (iii) LiAlH4, dry THF, 
reflux; (iv) phthalimide, PPh3, DIAD, dry THF, rt. 
 
 
 
 
Scheme 2. Reagents and conditions: (i) 10% HCl, THF, 0 °C then rt. 
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Scheme 3. Reagents and conditions: (i) phthalic anhydride, Et3N, toluene, 130 °C; (ii) gaseous 
HI, dry toluene, -5 °C then rt. 
 
 
 
 
Scheme 4. Reagents and conditions: (i) (CH3)SnN3, dry toluene, 110 °C; (ii) gaseous HCl, dry 
toluene/THF, 0 °C; (iii) CH3I, K2CO3, rt. then reflux. 
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Scheme 5. Reagents and conditions: (i) EEDQ, Et3N, CHCl3, reflux. 
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Scheme 6. Reagents and conditions: (i) NaNO3, TFA, rt, (ii) 10% Pd/C, abs EtOH, rt. 
 
 
 
 
Scheme 7. Reagents and conditions: (i) Et3N, toluene, reflux. 
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Scheme 8. Reagents and conditions: (i) phthalic anhydride, Et3N, toluene, reflux; (ii) 1-naphthol, 
PPh3, DEAD, anhyd THF, rt 
 
 
 
 
Scheme 9. Reagents and conditions: (i) tetrachlorophthalic anhydride, Et3N, toluene, reflux; (ii) 
phenol, PPh3, DEAD, anhyd THF, rt. 
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Scheme 10. Reagents and conditions: (i) thiophenol, K2CO3, anhyd DMF, reflux; (ii) 
tetrachlorophthalimide, PPh3, DEAD, anhyd THF, rt. 
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Scheme 11. Reagents and conditions: (i) phthalimide, PPh3, DIAD, dry THF, rt. 
  
 41
Chart 1. Compounds 1–52 
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Chart 2. Compounds 53–56 
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